30 Sep Heart Disease Linked to Severe Skin Reactions to Gout Medicine Allopurinol
Posted at 19:28h
in Allergies, Author Interviews, Brigham & Women's - Harvard, CMAJ, Dermatology, Heart Disease
MedicalResearch.com Interview with:
[caption id="attachment_51631" align="alignleft" width="120"]
Dr. Choi[/caption]
Hyon K. Choi, MD, DrPH
Professor of Medicine, Harvard Medical School
Director, Gout and Crystal Arthropathy Center
Director, Clinical Epidemiology and Health Outcomes
Division of Rheumatology, Allergy, and Immunology
Department of Medicine, Massachusetts General Hospital
MedicalResearch.com: What is the background for this study? What are the main findings?
Response: Allopurinol is a very common and generally safe medication prescribed to lower serum urate levels, most commonly to patients with gout. However, it can be associated with very rare but serious cutaneous adverse events which includes Stevens-Johnson syndrome and toxic epidermal necrolysis.
Prior studies have demonstrated several risk factors for these types of cutaneous adverse events, including presence of chronic kidney disease, older age, female sex, higher initial dose of allopurinol, and the HLA-B*5801 allele, which is more commonly found in Asians and Black patients. A prior study in Taiwan suggested that heart disease (ischemic heart disease and heart failure) may also be associated with an increased risk of hospitalizations for these cutaneous adverse reactions related to allopurinol.
Thus, our goal was to investigate this association using a general population cohort from Canada. Using Population Data BC, we found that heart disease was in fact independently associated with an increased risk of hospitalization for these cutaneous adverse reactions.
Dr. Hongying (Daisy) Dai[/caption]
Hongying (Daisy) Dai, PhD
Associate Professor
Department of Biostatistics | College of Public Health
University of Nebraska Medical Center
Omaha
MedicalResearch.com: What is the background for this study?
Response: Previous studies have reported a surge in e-cigarette use among youth during the 2017 - 2018. For instance, the prevalence of current (past 30-day) e-cigarette use increased by 77.8% (from 11.7% to 20.8%) among high school students and by 48.5% (from 3.3% to 4.9%) among middle school students.
As a result, the Food and Drug Administration (FDA) warns that youth e-cigarette use is reaching an epidemic proportion in September 2018. Whether e-cigarette use prevalence also increased among young adults (aged 18-24 years), a population with high e-cigarette use rates and vulnerability to nicotine dependence, is unknown.

